Shire PLC (NASDAQ:SHPG) – Analysts at SunTrust Banks lifted their Q3 2017 earnings per share (EPS) estimates for Shire PLC in a research note issued to investors on Monday. SunTrust Banks analyst J. Boris now expects that the biopharmaceutical company will earn $3.69 per share for the quarter, up from their prior forecast of $3.60. SunTrust Banks also issued estimates for Shire PLC’s Q4 2017 earnings at $3.92 EPS and FY2017 earnings at $14.97 EPS.
Other analysts also recently issued reports about the stock. Cantor Fitzgerald set a $222.00 target price on shares of Shire PLC and gave the stock a “buy” rating in a report on Saturday, July 1st. Stifel Nicolaus reiterated a “buy” rating and issued a $245.00 target price on shares of Shire PLC in a report on Wednesday, July 12th. BidaskClub downgraded shares of Shire PLC from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $210.00 target price on shares of Shire PLC in a report on Thursday, July 13th. Finally, BTIG Research reiterated a “buy” rating and issued a $242.00 target price on shares of Shire PLC in a report on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and thirteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $220.91.
ILLEGAL ACTIVITY NOTICE: “Q3 2017 EPS Estimates for Shire PLC (SHPG) Lifted by SunTrust Banks” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/28/q3-2017-eps-estimates-for-shire-plc-shpg-lifted-by-suntrust-banks.html.
Shares of Shire PLC (NASDAQ SHPG) opened at 146.29 on Thursday. Shire PLC has a 12 month low of $139.36 and a 12 month high of $192.64. The firm has a market cap of $43.57 billion, a P/E ratio of 65.45 and a beta of 1.63. The company has a 50-day moving average of $154.03 and a 200-day moving average of $164.51.
Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 EPS for the quarter, missing the Zacks’ consensus estimate of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%.
The business also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Shareholders of record on Friday, September 8th will be paid a $0.1527 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a yield of 0.21%. Shire PLC’s dividend payout ratio is presently 41.07%.
A number of institutional investors have recently added to or reduced their stakes in the business. Afam Capital Inc. increased its stake in Shire PLC by 8.8% in the 2nd quarter. Afam Capital Inc. now owns 29,879 shares of the biopharmaceutical company’s stock valued at $4,938,000 after buying an additional 2,410 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Shire PLC in the 2nd quarter valued at approximately $406,000. Verition Fund Management LLC increased its stake in Shire PLC by 18.9% in the 2nd quarter. Verition Fund Management LLC now owns 2,967 shares of the biopharmaceutical company’s stock valued at $490,000 after buying an additional 472 shares during the period. Sterling Capital Management LLC acquired a new position in Shire PLC in the 2nd quarter valued at approximately $299,000. Finally, Delphi Management Inc. MA increased its stake in Shire PLC by 10.5% in the 2nd quarter. Delphi Management Inc. MA now owns 13,350 shares of the biopharmaceutical company’s stock valued at $2,206,000 after buying an additional 1,270 shares during the period. Hedge funds and other institutional investors own 19.24% of the company’s stock.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.